Human plasminogen activator inhibitor-1 (PAI-1) deficiency: characterization of a large kindred with a null mutation in the PAI-1 gene.

No abstract is available for this paper.

• Publication year

  1997

• Venue

  Blood

• Publication date

  1997-07-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1182/BLOOD.V90.1.204.204_204_208PMID 9207454
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene.

  1996cited by this paper
• High concentrations of active plasminogen activator inhibitor-1 in porcine coronary artery thrombi.

  1996cited by this paper
• Biological Effects of Combined Inactivation of Plasminogen Activator and Plasminogen Activator Inhibitor-1 Gene Function in Mice

  1995cited by this paper
• Structure of plasminogen activator inhibitor 1 (PAI-1) and its function in fibrinolysis: an update

  1995cited by this paper
• Plasminogen deficiency causes severe thrombosis but is compatible with development and reproduction.

  1995cited by this paper
• Effects of disruption of the plasminogen gene on thrombosis, growth, and health in mice.

  1995cited by this paper
• The serpin superfamily of proteinase inhibitors: structure, function, and regulation.

  1994cited by this paper
• Evaluation of the plasminogen/plasmin system in transgenic mice

  1994cited by this paper
• Physiological consequences of loss of plasminogen activator gene function in mice

  1994cited by this paper
• Plasminogen activator inhibitor-1 gene-deficient mice. II. Effects on hemostasis, thrombosis, and thrombolysis.

  1993cited by this paper
• Plasminogen activator inhibitor-1 gene-deficient mice. I. Generation by homologous recombination and characterization.

  1993cited by this paper
• Predictive value for thrombotic disease of plasminogen activator inhibitor-1 plasma levels

  1993cited by this paper
• Deficiency of plasma plasminogen activator inhibitor 1 results in hyperfibrinolytic bleeding.

  1993cited by this paper
• Plasminogen activator inhibitor-1 deposition in the extracellular matrix of cultured human mesangial cells.

  1992cited by this paper
• Brief report: complete deficiency of plasminogen-activator inhibitor type 1 due to a frame-shift mutation.

  1992cited by this paper
• Immunoelectron Microscopic Localization of Type 1 Plasminogen Activator Inhibitor in the Extracellular Matrix of Transforming Growth Factor‐β‐Activated Endothelial Cells

  1992cited by this paper
• Saturation mutagenesis of the plasminogen activator inhibitor-1 reactive center.

  1992cited by this paper
• Thrombin neutralizes plasminogen activator inhibitor 1 (PAI-1) that is complexed with vitronectin in the endothelial cell matrix

  1991cited by this paper
• A lifelong bleeding disorder associated with a deficiency of plasminogen activator inhibitor type 1.

  1991cited by this paper
• Both circulating and clot-bound plasminogen activator inhibitor-1 inhibit endogenous fibrinolysis in the rat.

  1991cited by this paper
• Platelet-derived growth factor and transforming growth factor-beta regulate plasminogen activator inhibitor-1 synthesis in vascular smooth muscle cells.

  1991cited by this paper
• Structure of Vitronectin and its Biological Role in Haemostasis

  1991cited by this paper
• Vitronectin governs the interaction between plasminogen activator inhibitor 1 and tissue-type plasminogen activator.

  1991cited by this paper
• Alteration of serpin specificity by a protein cofactor. Vitronectin endows plasminogen activator inhibitor 1 with thrombin inhibitory properties.

  1990cited by this paper
• [Type 1 plasminogen activator inhibitor].

  1990cited by this paper
• Interactions between type 1 plasminogen activator inhibitor, extracellular matrix and vitronectin.

  1990cited by this paper
• Type 1 plasminogen activator inhibitor.

  1989cited by this paper
• Bleeding diathesis due to decreased functional activity of type 1 plasminogen activator inhibitor.

  1989cited by this paper
• Fibrinolytic system of vascular endothelial cells. Role of plasminogen activator inhibitors.

  1988cited by this paper
• Fibrinolytic System of Vascular Endothelial Cells

  1988cited by this paper
• Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction.

  1987cited by this paper
• Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction.

  1985cited by this paper

• Reversing PAI-1 deficiency in blood using mRNA lipid nanoparticles

  2025cites this paper
• Perinatal Intracranial Hemorrhage as a Rare Presentation of Plasminogen Activator Inhibitor-1 (PAI-1) Deficiency: A Case Report

  2025cites this paper
• Thermodynamics and selection of the plasminogen activator inhibitor-1 latency transition

  2025cites this paper
• Comprehensive Review of Thrombophilia: Pathophysiology, Prevalence, Risk Factors, and Molecular Diagnosis.

  2025cites this paper
• Not in the beginning.

  2025cites this paper
• Transcriptome Analysis Identified SPP1‐Positive Monocytes as a Key in Extracellular Matrix Formation in Thrombi

  2025cites this paper
• Role of plasminogen activator inhibitor-1 (PAI-1) in age-related cardiovascular pathophysiology.

  2025cites this paper
• Plasminogen activator inhibitor 1 promotes aortic aging–like pathophysiology in humans and mice

  2025cites this paper
• Genome-wide DNA methylation and transcriptomic analysis of liver tissues subjected to early ischemia/reperfusion injury upon human liver transplantation.

  2024cites this paper
• Assessment of rare bleeding disorders in adolescents with heavy menstrual bleeding

  2024cites this paper
• Targeted exome analysis in patients with rare bleeding disorders: data from the Rare Bleeding Disorders in the Netherlands study

  2024cites this paper
• Disorders of Coagulation in the Newborn.

  2024cites this paper
• Lethal COVID-19 associates with RAAS-induced inflammation for multiple organ damage including mediastinal lymph nodes

  2024cites this paper
• Transcriptome Analysis Identified SPP1+ Monocytes as a Key in Extracellular Matrix Formation in Thrombi

  2024cites this paper
• Time-dependent ultrastructural changes during venous thrombogenesis and thrombus resolution.

  2024cites this paper
• Rare inherited coagulation and fibrinolytic defects that challenge diagnostic laboratories

  2023cites this paper
• Lethal COVID-19 Associates With RAAS-Induced Inflammation For Multiple Organ Damage Including Mediastinal Lymph Nodes

  2023cites this paper
• “Super” SERPINs—A stabilizing force against fibrinolysis in thromboinflammatory conditions

  2023cites this paper
• Plasminogen activator inhibitor 1 is not a major causative factor for exacerbation in a mouse model of SARS-CoV-2 infection

  2023cites this paper
• Cysteine and methionine oxidation in thrombotic disorders.

  2023cites this paper
• Identification of Genomic Loci Regulating Platelet Plasminogen Activator Inhibitor-1 in Mice.

  2023cites this paper
• The role of the platelet pool of Plasminogen Activator Inhibitor-1 in well-controlled type 2 diabetes patients

  2022cites this paper
• Deep mutational scanning and massively parallel kinetics of plasminogen activator-1 functional stability

  2022cites this paper
• Oxidative Stress and Extracellular Matrix Remodeling Are Signature Pathways of Extracellular Vesicles Released upon Morphine Exposure on Human Brain Microvascular Endothelial Cells

  2022cites this paper
• Genetic Variations miR-10aA>T, miR-30cA>G, miR-181aT>C, and miR-499bA>G and the Risk of Recurrent Pregnancy Loss in Korean Women

  2022cites this paper
• Past, Present, and Future Perspectives of Plasminogen Activator Inhibitor 1 (PAI-1)

  2022cites this paper
• Case-only design identifies interactions of genetic risk variants at SIGLEC5 and PLG with the lncRNA CTD-2353F22.1 implying the importance of periodontal wound healing for disease aetiology.

  2022cites this paper
• PAI-1: A Major Player in the Vascular Dysfunction in Obstructive Sleep Apnea?

  2022cites this paper
• Fibrinolytic assays in bleeding of unknown cause: Improvement in diagnostic yield

  2022cites this paper
• Deep mutational scanning and massively parallel kinetics of plasminogen activator inhibitor-1 functional stability to probe its latency transition

  2022cites this paper
• Deep mutational scanning and massively parallel kinetics of plasminogen activator inhibitor-1 functional stability

  2022cites this paper
• Plasminogen Activator Inhibitor-1 and Oncogenesis in the Liver Disease

  2021cites this paper
• Network medicine for disease module identification and drug repurposing with the NeDRex platform

  2021cites this paper
• Bleeding Disorders in Primary Fibrinolysis

  2021cites this paper
• Evening chronotype is associated with elevated biomarkers of cardiometabolic risk in the EpiHealth cohort: a cross-sectional study

  2021cites this paper
• Prevalence and Multiplicity of Thrombophilia Genetic Polymorphisms of FV, MTHFR, FII, and PAI-I: A Cross-Sectional Study on a Healthy Jordanian Population

  2021cites this paper
• A Serpin With a Finger in Many PAIs: PAI-1's Central Function in Thromboinflammation and Cardiovascular Disease

  2021cites this paper
• The multiomics landscape of serum exosomes during the development of sepsis

  2021cites this paper
• Polycystic οvary syndrome revisited: An interactions network approach

  2021cites this paper
• Pharmacogenomic considerations for repurposing of dexamethasone as a potential drug against SARS-CoV-2 infection

  2021cites this paper
• Deep mutational scanning of the plasminogen activator inhibitor-1 functional landscape

  2021cites this paper
• Porphyromonas gingivalis Gingipains-Mediated Degradation of Plasminogen Activator Inhibitor-1 Leads to Delayed Wound Healing Responses in Human Endothelial Cells

  2021cites this paper
• Molecular basis of hemostatic and thrombotic diseases

  2020cites this paper
• Targeting PAI-1 in Cardiovascular Disease: Structural Insights Into PAI-1 Functionality and Inhibition

  2020cites this paper
• Inhibition of PI3Kγ by AS605240 plus low-dose tissue plasminogen activator (tPA) combination improves thrombolytic therapy in a rat model of embolic stroke.

  2020cites this paper
• PAI-1, the Plasminogen System, and Skeletal Muscle

  2020cites this paper
• Physiology of Haemostasis: Plasmin-Antiplasmin System

  2020cites this paper
• Functional Characterization of Fibrinolysis-Modulating Proteins Using High Throughput Phage Display

  2020cites this paper
• SERPINE1 Gene

  2020cites this paper
• Specific inhibition of plasminogen activator inhibitor 1 reduces blood glucose level by lowering TNF-α.

  2020cites this paper
• Congenital PAI-1 deficiency results in psoas hematoma in an Indian patient.

  2020cites this paper
• The use of prophylaxis in the treatment of rare bleeding disorders.

  2020cites this paper
• Fibrinolytic Pathway Disorders

  2020cites this paper
• Phosphoproteomics of Acute Cell Stressors Targeting Exercise Signaling Networks Reveal Drug Interactions Regulating Protein Secretion.

  2019cites this paper
• The utility of thromboelastography and tranexamic acid in plasminogen activator inhibitor deficiency during pregnancy: a rare case report.

  2019cites this paper
• Thrombin and plasmin generation in patients with plasminogen or plasminogen activator inhibitor type 1 deficiency

  2019cites this paper
• Regulation of Fibrinolysis by Platelets

  2019cites this paper
• Sparganin A alleviates blood stasis syndrome and its key targets by molecular docking

  2019cites this paper
• Modulation of connective tissue growth factor and activin receptor 2b function in cardiac hypertrophy and fibrosis

  2019cites this paper
• Endothelial PAI-1 (Plasminogen Activator Inhibitor-1) Blocks the Intrinsic Pathway of Coagulation, Inducing the Clearance and Degradation of FXIa (Activated Factor XI).

  2019cites this paper
• Complete Plasminogen Activator Inhibitor 1 Deficiency -- GeneReviews®

  2019cites this paper
• Diagnostic challenges of inherited mild bleeding disorders: a bait for poorly explored clinical and basic research

  2019cites this paper
• Bioinformatics-based analysis of the involvement of AC005550.3, RP11-415D17.3, and RP1-140K8.5 in homocysteine-induced vascular endothelial injury.

  2018cites this paper
• Proteolysis is the most fundamental property of malignancy and its inhibition may be used therapeutically (Review)

  2018cites this paper
• Hemorrhagic disorders of fibrinolysis: a clinical review

  2018cites this paper
• Primary hyperfibrinolysis: Facts and fancies.

  2018cites this paper
• DNA methylation age is associated with an altered hemostatic profile in a multiethnic meta-analysis.

  2018cites this paper
• Physiology and pathophysiology of the plasminogen system in the kidney

  2017cites this paper
• Hemostatic function to regulate perioperative bleeding in patients undergoing spinal surgery: A prospective observational study

  2017cites this paper
• Platelets and Fibrinolysis

  2017cites this paper
• Plasminogen Activator Inhibitor-1 Is a Marker and a Mediator of Senescence.

  2017cites this paper
• Causal Effect of Plasminogen Activator Inhibitor Type 1 on Coronary Heart Disease

  2017cites this paper
• A hydrophobic patch surrounding Trp154 in human neuroserpin controls the helix F dynamics with implications in inhibition and aggregation

  2017cites this paper
• Current and Emerging Medical Treatments for Uterine Fibroids

  2017cites this paper
• A null mutation in SERPINE1 protects against biological aging in humans

  2017cites this paper
• 19 – Investigation of a Thrombotic Tendency

  2017cites this paper
• Quantitative proteomics reveals divergent responses in Apis mellifera worker and drone pupae to parasitization by Varroa destructor.

  2017cites this paper
• Role of Plasminogen Activator Inhibitor Type 1 in Pathologies of Female Reproductive Diseases

  2017cites this paper
• Plasminogen Activator Inhibitor Type I Controls Cardiomyocyte Transforming Growth Factor-&bgr; and Cardiac Fibrosis

  2017cites this paper
• Protease Injury in the Development of COPD

  2017cites this paper
• A long-acting PAI-1 inhibitor reduces thrombus formation

  2017cites this paper
• Abnormal Uterine Bleeding including coagulopathies and other menstrual disorders.

  2017cites this paper
• Differential response of plasma plasminogen activator inhibitor 1 after weight loss surgery in patients with or without type 2 diabetes.

  2017cites this paper
• Generation of human iPSCs from urine derived cells of a non-affected control subject.

  2017cites this paper
• Plasmin-Antiplasmin System

  2016cites this paper
• Bleeding related to disturbed fibrinolysis

  2016cites this paper
• Abnormalities in the fibrinolysis pathway and clinical implications

  2016cites this paper
• Generation of human iPSCs from urine derived cells of a patient with a novel homozygous PAI-1 mutation.

  2016cites this paper
• Evaluating for Suspected Child Abuse: Conditions That Predispose to Bleeding

  2016cites this paper
• Genomica: riesgo y resultados en cirugõ´ ac ardõaca

  2016cites this paper
• Aspects of Plasminiogen Activator Inhibitor 1 in Metabolic Syndrome

  2016cites this paper
• Pharmacogenomics of non-steroidal antiinflammatory drug-induced gastrointestinal complications

  2016cites this paper
• Generation of human iPSCs from urine derived cells of patient with a novel heterozygous PAI-1 mutation

  2016cites this paper
• Thrombolysis: A Critical First-Line Therapy with an Unfulfilled Potential.

  2016cites this paper
• Challenges of diagnosing and managing the adolescent with heavy menstrual bleeding.

  2016cites this paper
• Plasminogen Activator Inhibitor-1 in Cancer: Rationale and Insight for Future Therapeutic Testing.

  2015cites this paper
• Macrophages of M1 phenotype have properties that influence lung cancer cell progression

  2015cites this paper
• Application of Long-Acting VLHL PAI-1 during Sutureless Partial Nephrectomy in Mice Reduces Bleeding

  2015cites this paper
• Severe Hemorrhagic Diathesis in a Patient with Prostat Adenocarsinoma and Diagnostic Approach

  2015cites this paper
• Comparison between the clot-protecting activity of a mutant plasminogen activator inhibitor-1 with a very long half-life and 6-aminocaproic acid.

  2015cites this paper